Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Personalized Medicine

Aug 14

Written By Matthijs Versteegh

personalized medicineOncology

Matthijs Versteegh

HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model